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Abstract
Pharmacokinetic modelling on dynamic positron emission tomography (PET) data is a quantitative technique. However,
the long acquisition time is prohibitive for routine clinical use. Instead, the semi-quantitative standardised uptake value
ratio (SUVR) from a shorter static acquisition is used, despite its sensitivity to blood flow confounding longitudinal analysis.
A method has been proposed to reduce the dynamic acquisition time for quantification by incorporating cerebral blood
flow (CBF) information from arterial spin labelling (ASL) magnetic resonance imaging (MRI) into the pharmacokinetic
modelling. In this work, we optimise and validate this framework for a study of ageing and preclinical Alzheimer’s disease.
This methodology adapts the simplified reference tissue model (SRTM) for a reduced acquisition time (RT-SRTM) and is
applied to [18F]-florbetapir PET data for amyloid-b quantification. Evaluation shows that the optimised RT-SRTM can
achieve amyloid burden estimation from a 30-min PET/MR acquisition which is comparable with the gold standard
SRTM applied to 60min of PET data. Conversely, SUVR showed a significantly higher error and bias, and a statistically
significant correlation with tracer delivery due to the influence of blood flow. The optimised RT-SRTM produced amyloid
burden estimates which were uncorrelated with tracer delivery indicating its suitability for longitudinal studies.
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Introduction
Positron emission tomography (PET) facilitates the
quantiﬁcation of a range of important biomarkers
through the injection and detection of targeted radio-
tracers. To interpret the measured signal and derive the
biological parameters of interest, data are collected
dynamically from injection, covering radiotracer deliv-
ery to tissue, interaction with the target, and tracer
washout. This provides a map of the spatio-temporal
concentration of the tracer in vivo. A pharmacokinetic
model which describes these processes may then be
ﬁtted to these dynamic data to estimate the biological
parameters such as radiotracer target density.
Depending on the radiotracer administered, the
dynamic data acquisition time required to ﬁt the model
may be 60min or more. This is prohibitive in a clinical
context due to patient discomfort, restrictions on scanner
time availability, and the increased chance of subject
motion which corrupts the data. Consequently, a simpli-
ﬁed technique is commonly employed.
The standardised uptake value ratio (SUVR) is a
measure of relative tracer uptakewhich can be calculated
from a static scan lasting approximately 10min. SUVR
is calculated by dividing the tracer concentration within
the tissue of interest by the concentration in a reference
region. The reference region consists of tissue considered
to be free of the radiotracer target and represents the
non-displaceable (ND) tracer concentration (i.e. tracer
in the tissue which is not bound to the intended target).
When the ratio of the tracer concentration within the
target tissue and the reference tissue has reached a
steady-state, SUVR approximates the distribution
volume ratio (DVR). DVR can be estimated from phar-
macokinetic modelling and is related to target density.
However, as SUVR is calculated from a single static
scan, the tracer concentration present during the acqui-
sition will depend on the delivery of the tracer, as well as
target density. Tracer delivery is intrinsically linked to
blood ﬂow, and since blood ﬂow can change during the
progression of disease,1 and indeed ﬂuctuate over the
course of a day,2 SUVR estimates may be confounded.
The inﬂuence of cerebral blood ﬂow (CBF) changes
on SUVR estimates has been highlighted in longitu-
dinal Alzheimer’s disease studies in which the target
of interest was the protein amyloid-b. Amyloid-b is
an early indicator of disease onset and a therapeutic
target, hence accurately quantifying amyloid-b density
is of paramount importance. Here, variation in blood
ﬂow has been shown to cause spurious changes in
SUVR which are unrelated to target density.3,4
Conversely, target density estimates derived from phar-
macokinetic modelling of dynamic data starting from
radiotracer injection can account for blood ﬂow, as
tracer delivery is parameterised within the model.
Dynamic PET data can be divided into two phases:
the early phase, in which the signal is dominated by
tracer delivery to tissue,5 and the late phase, which con-
tains information related to tracer binding and wash-
out, and is where SUVR is estimated. The intrinsic
correlation between tracer delivery and CBF has been
demonstrated for an amyloid-b tracer.6 Therefore,
if CBF can be measured independently from the PET
acquisition, then the data acquisition time may be
reduced such that only the late phase data are acquired
to estimate the remaining parameters.
Arterial spin labelling (ASL) magnetic resonance
imaging (MRI) is a non-invasive imaging technique
which applies a magnetic ‘tag’ to arterial blood, such
that it can be used as an endogenous contrast agent.
ASL can be used to estimate CBF, as validated by com-
parison with the gold standard radiolabelled water
PET.7 While the accuracy of the technique is dependent
on the implementation, high quantitative accuracy has
been achieved when ASL data are normalised to a ref-
erence region.8
The introduction of combined PET/MRI scanners,
which facilitate simultaneous acquisition, means that
ASL and late phase PET data can be acquired concur-
rently. By incorporating CBF information from ASL
into the PET pharmacokinetic modelling to provide
early phase delivery information, the total acquisition
time can be signiﬁcantly reduced, increasing patient
comfort and throughput, without sacriﬁcing quantita-
tive accuracy.
In this paper, we build on the framework which
combines ASL-derived CBF data with PET kinetic
modelling to reduce the acquisition time from 60 to
30min.9 This is referred to here as the reduced acquisi-
tion time simpliﬁed reference tissue model (RT-
SRTM). In the present work, the relationship between
PET radiotracer delivery and ASL measured CBF is
investigated with a larger group of subjects. An
improved methodology for the estimation of the early
phase data is proposed and compared to that used pre-
viously.9 Finally, the timing of the late phase acquisi-
tion is optimised before applying the improved
methodology to a diﬀerent set of subjects. This was
applied to [18F]-ﬂorbetapir amyloid PET data from a
study of ageing and preclinical Alzheimer’s disease.
Material and methods
PET kinetic modelling
The simpliﬁed reference tissuemodel (SRTM)10was used
as the gold standard for PET pharmacokinetic model-
ling, as it is commonly applied in amyloid studies5,6,11,12
and has been validated against pharmacokinetic model-
ling with arterial sampling for [18F]-ﬂorbetapir.13 The
SRTM employs a reference region, which is considered
to be devoid of the imaging target, to replace the plasma
input function. Cerebellar grey matter was used as it is
assumed to be devoid of amyloid-b.14
The operational equation between the tracer concen-
tration in the target tissue CT tð Þ and the reference
region CR tð Þ is formulated as shown in equation (1).
Here t denotes time with tracer injection at t ¼ 0, and
 represents the convolution operator
CT tð Þ ¼R1CR tð Þþ k2R1 k2
1þBPND
 
CR tð Þ e
k2
1þBPND t
ð1Þ
The SRTM contains three parameters: R1, which is
the rate constant of tracer delivery to the target tissue
relative to the reference tissue; k2, which is the rate
constant from target tissue to blood; and the ND bind-
ing potential BPND, which is proportional to target
density, i.e. the density of amyloid-b, see
Supplementary Materials.
An in-house implementation of the SRTM using the
basis function method15 was ﬁtted to the PET data to
derive regional gold standard parameter estimates,
denoted by an asterisk, of BPND, k

2 and R

1 from
dynamic PET data conventionally acquired for
t 2 0, 60½  min, denoted here as t ¼ 0, 60 min. For
more details see Supplementary Materials.
PET kinetic modelling with reduced acquisition time
Early PET signal is dominated by the delivery of the
tracer to the tissue and hence is important for the esti-
mation of R1. The later part of the signal contains
information about the binding of the tracer to the
target and its subsequent washout, which is essential
for the estimation of k2 and BPND.
Consequently, if the blood ﬂow information can be
estimated independently from the PET data, then the
acquisition time can be reduced, by recording only the
late signal to allow the estimation of k2 and BPND. This
requires two modiﬁcations to the model: (i) the estima-
tion of R1 from another source, and (ii) extrapolation
of the reference region curve, CR to t ¼ 0, as the model
contains a convolution term which requires the full time
series from injection to compute. Here, we refer to this
modiﬁed model as the reduced acquisition time SRTM
(RT-SRTM).
Derivation of PET-R1 from ASL–CBF
R1 is deﬁned as R1 ¼ K1=K01 where K1 is the transfer
rate constant from blood to target tissue and K01 is the
transfer rate constant from blood to reference tissue.
According to the Renkin–Crone16,17 capillary model,
the relationship between tracer delivery, K1, and
blood ﬂow, F, can be described as
K1 ¼ EF ¼ 1 ePSF
 
F ð2Þ
The Renkin–Crone model includes a term for the net
extraction of the tracer from the capillaries, E, which is
dependent on the vessel permeability surface area prod-
uct, PS. Under common physiological ﬂow conditions,
where PS=F is high (3), the relationship between K1
and ﬂow F is approximately linear. If we assume that
PS is suﬃciently high, the relationship between K1 and
F, and in turn the relationship between R1 and F, can
be approximated as a linear function,6 as expressed in
equation (3)
R1 ¼ K1
K01
¼ 0 þ 1 F
F0
ð3Þ
ASL can be used to measure the CBF, F, and may
be converted into an R1 estimate to use in the RT-
SRTM, using the relationship from equation (3),
where F0 indicates the CBF measured in the reference
region.
In this study, linear regression between R1 and CBF
was performed in a group of subjects to determine
whether this approximation is valid. The slope and
intercept of the linear regression, 0 and 1, can
account for systematic diﬀerences between the modal-
ities and an extraction fraction of E5 100 %. The
derived 0 and 1 can then be applied to a diﬀerent
group of subjects to convert ASL-CBF to a derived
R1 value.
Due to systematic errors in ASL-CBF estimates in
certain regions of the brain, particularly for single
inversion time ASL data,7 multi-linear analysis was
also performed, to determine whether 0 and 1 may
be region dependent. Multi-linear regression has
the capacity to model interaction terms between
ASL-CBF and the region and can be described as in
equation (4)
R1 ¼ 0 þ 1 F
F0
þ
Xregions
n¼2
nI regionn½ 
þ
X2regions
m¼regionsþ1
m  F
F0
 I½regionm
ð4Þ
Here regionn½  is equal to 1 when regionn is being
considered, and 0 otherwise. Two further multi-linear
analyses were also performed (i) using the subject as a
covariate, and (ii) using both subject and regions as
covariates to determine their relative inﬂuence on R1
estimation.
Extrapolation of PET reference region, CR tð Þ. To compute the
convolution term in equation (1), CR must be known
from injection, at t ¼ 0, to the end of the scan, t ¼ te,
where ts, te ¼ 0, 60 min for the gold standard. However,
when reducing the acquisition time, CR is only mea-
sured between ts and te where ts 6¼ 0, and therefore a
strategy is required to extrapolate the missing data.
Here we deﬁne CRðtÞ as a vector containing the refer-
ence region tracer concentration over time, C
pop
R tð Þ as a
matrix containing the reference region concentration
for a population of subjects, and CpopR tð Þ as a vector con-
taining the mean population tracer concentration. For
clarity, the acquisition time, t, is expressed as a discrete
variable, as the dynamic data are binned into frames.
In this work, two diﬀerent approaches are evaluated
to estimate the whole reference input vector CR t ¼ 0,te½ 
for an unseen subject’s CR t ¼ ts,te½ . Both techniques
make use of a population of subjects for which the
full CR t ¼ 0,te½  was measured.
The ﬁrst method, referred to as the scaled mean CR
method and proposed by Scott et al.,9 scales the popu-
lation average reference region curve, CpopR½t¼0, te, as
CR t¼0,te½    CpopR½t¼0,te ð5Þ
where  is a subject speciﬁc scaling factor determined
through a least squares ﬁt of CpopR½t¼ts, te to CR t¼ts,te½ . This
results in an individual estimate of CR t¼0,te½  to be used
in the RT-SRTM.
The second method employs statistical shape model-
ling to build a model of the variation in CR within the
population of subjects.18 This requires principal com-
ponent analysis (PCA) of a set of subjects to determine
the M components, U ¼ u1!, . . . , uM! 0 where ui!¼
u1, . . . , uframes
 
, and is therefore referred to as the
PCA CR method.
The CR t ¼ 0,te½  of each subject in the set can be
expressed as the mean population reference curve,
CpopR½t¼0, te, plus a linear combination of the weighted
principal components, where the weight of the ith
mode, ui
!, is wi. A subset, L where L5M, of the com-
ponents which describe the majority of the variation are
selected. An unseen reference region curve CR t¼ts ,te½  can
then be ﬁtted by adjusting the weights, as per equation
(6). The same weights and modes can then be used
with C
pop
R t¼0,te½ 
to generate CR t¼0,te½  . See Supplementary
Materials for more details
CR t¼ts , te½   CpopR t¼ts, te½  þ
XL
i¼1
wi ui
! ð6Þ
Fitting the SRTM with CBF-derived R1 and extrapolated CR. To
apply the modiﬁcations to the SRTM with reduced
acquisition time, the operational equation in (1) is re-
written as in equation (7). This groups the measured
parameter CTðtÞ, with the derived CRðtÞ and derived
R1 into a dummy variable, C
z
T tð Þ, as they are deter-
mined prior to ﬁtting
C
z
T tð Þ ¼ CT tð Þ  R1CR tð Þ ¼ CR tð Þ  et
where
 ¼ k2  R1 k2ð1þ BPNDÞ ,  ¼
k2
ð1þ BPNDÞ ð7Þ
To solve equation (7) for a reduced acquisition time
where t ¼ ts, te, the basis function approach15 is used to
pre-calculate the convolution term using the extrapo-
lated CRðt ¼ 0, teÞ with a range of biologically plausible
values for . A least squares ﬁt to the pre-determined
data, C
z
T t ¼ ts, teð Þ, is performed for each  to estimate
, and the instance of  which yields the lowest sum of
squares diﬀerence is selected. BPND and k2 are then
derived from ,  and the CBF-derived R1. For more
details, including the pseudo-code, see Supplementary
Materials.
Data
Imaging data were collected from 60 cognitively normal
subjects participating in Insight 46, a neuroimaging sub-
study of the Medical Research Council National Survey
of Health and Development,19 and 4 subjects from a
study of young onset Alzheimer’s Disease (YOAD)
with an intermediate or high certainty diagnosis.20
These studies were conducted in line with the principles
of the Declaration of Helsinki. For Insight 46, ethical
approval was obtained from the National Research
Ethics Service (ref 14/LO/1173), and for YOAD,
approval was obtained from the London Queen
Square Ethics Committee (ref 15/LO/1412). Written
informed consent was obtained from all participants.
All subjects underwent 60min of simultaneous amyl-
oid PET and multi-modal MR imaging on a Siemens
Biograph mMR PET/MR scanner. Of the 64 subjects
used for analysis, mean age 69.6 years (range 61.7–70.5
years), 45 had both PET and ASL data, and for 19 the
ASL data were missing, either due to repetition of other
scans (4) or imaging artefacts (15).
The subjects were divided into 2 sets; an optimisa-
tion set containing 39 subjects, and a testing set con-
taining the remaining 25 subjects, see Figure 1. The
clinically diagnosed YOAD subjects were evenly split
between the two sets, as were amyloid positive (aþ)
subjects from Insight 46. Amyloid positivity was
deﬁned using mean cortical grey matter SUVR with a
whole cerebellum reference region, see Supplementary
Materials for details.
Within the optimisation set, the 20 subjects with PET
and ASL data were used to derive the relationship
between PET-R1 and ASL-CBF. The whole optimisa-
tion set was used to optimise the extrapolation of CR
and the acquisition timing window using leave-one-out
cross validation. Finally, the relationship between PET-
R1 and ASL-CBF and the optimised CR method from
the optimisation set was used to apply the RT-SRTM to
the 25 testing set subjects, see Supplementary Materials.
CBF estimation from ASL MRI
CBF was estimated from a pseudo-continuous ASL
(pCASL) acquisition with the following parameters:
3D GRASE readout21 with 36 partitions and a recon-
structed voxel size of 1:88 1:88 4 mm, TE/
TR¼20.3/4000ms, 4-shot with turbo-factor/EPI-
factor¼14/28, bandwidth 2298Hz/pixel; 10 control-
label pairs were acquired with a pulse duration ()
and post labelling delay (PLD) both equal to 1800ms.
Acquisition time was 5min 20 s (t ¼ 55, 60). CBF maps
were computed with equation (8) 22
CBF ¼ 6000
2
S
S0
e
PLD
T1blood
T1bloodð1 e=T1blood Þ
ml
100g
=min
	 

ð8Þ
with 0.9ml/g for the plasma/tissue partition coeﬃcient
(), a blood T1 of 1650ms (T1blood), and a labelling
eﬃciency of 0.85 () as recommended in the ASL con-
sensus paper.23 S is the signal diﬀerence between the
control and label images, S0 maps were estimated by
ﬁtting saturation recovery images acquired with the
same sequence at three diﬀerent saturation times
(1,2,4 s) using NiftyFit.24
Dynamic PET acquisition and reconstruction
List mode PET data were acquired for 60min following
intravenous injection of [18F]-ﬂorbetapir, which targets
amyloid-b. For PET image reconstruction, simultan-
eously acquired structural T1- and T2-weighted MR
images were used to synthesise CT data and calculate
the attenuation map (-map),25 as validated in
Ladefoged et al.26 The -map was propagated into
PET space by registering the T1-weighted images to a
full 60-min non-attenuation-corrected reconstructed
PET image.
Dynamic PET data were binned into 31 time frames
(15 s 4, 30 s  8, 60 s 9, 180 s 2, 300 s 8), and
reconstructed into 222mm voxels using the open
source NiftyPET package.27 An ordered subset expect-
ation maximisation (OSEM) algorithm was used with 4
iterations, 14 subsets, and a 2mm Gaussian ﬁlter,
accounting for dead-time, attenuation, scatter, ran-
doms and normalisation.
Regional analysis
T1-weighted MR images were parcellated into 17
regions: accumbens, amygdala, brainstem, caudate,
cerebellum (white and grey separately), hippocampus,
cerebral white matter, pallidum, putamen, thalamus
and six cortical grey matter regions, with left and
right hemispheres combined;28 16 regions were used
for analysis, excluding the reference region.
Analysis was performed in native space such that the
T1-weighted MR image was rigidly registered to both
ASL (saturation recovery image target) and PET (m-
map transformation) space, and the transformation
was propagated to the parcellation.29
Statistical analysis
To compare diﬀerent techniques with the gold standard,
mean square error (MSE ¼ 1n
Pn
i¼1 Yi  Yi
 2
and mean
error MSE ¼ 1n
Pn
i¼1 Yi  Yi
  
were used, where n is
the number of estimates, Yi is the gold standard estimate
or measured value and Yi is the estimate being evalu-
ated. To compare diﬀerent techniques, statistical signiﬁ-
cance was tested using paired, two-tailed Wilcoxon
signed-rank test for MSE (as the data are not normally
distributed), and paired two-tailed t-tests for ME.
Results
Relationship between ASL–CBF and PET-R1
Figure 2(a) shows the relationship between PET-R1 and
ASL-CBF across the 16 regions for 20 optimisation set
subjects. Linear regression shows a statistically
Whole dataset
64 subjects (11 a + [17%])
PET & ASL
45 subjects
PET only
19 subjects
Optimisation set
39 subjects (6 a + [15%])
CBF and R1 relationship
20 subjects (4 a + [20%])
PET & ASL
20 subjects
PET only
19 subjects
CR extrapolation
39 subjects (6 a + [15%])
PET & ASL 
20 subjects
PET & ASL
20 subjects
PET only
19 subjects
Testing set
25 subjects (5 a + [20%])
PET & ASL
25 subjects
PET only
0 subjects
PET only
0 subjects
Figure 1. Flow chart describing data division between opti-
misation and testing sets, with the number of subjects defined as
amyloid positive (aþ) using SUVR with a whole cerebellum
reference region.
signiﬁcant correlation between the two parameters
(	¼ 0.349, p5 0.001); however, there is some variabil-
ity which is not explained by this linear model. Noise
and artefacts in the ASL data are considered to be the
main causes of the variability; however, violations of
the model assumptions may also contribute.
Residual analysis was performed to determine
whether a non-linear model could be ﬁtted to the
data, as suggested by equation (2). The normality plot
for the residual error in Figure 2(a) is shown in
Figure 2(b). This demonstrates that the residuals
follow an approximately normal distribution, which
supports the use of a linear model. However, there is
some deviation from normality at the extremes, which
is illustrated by the histogram inset in Figure 2(b). This
shows that there are some outlying positive residuals
which skew the distribution.
To quantify the regional and subject eﬀects, multi-
linear analysis was also performed. Multi-linear regres-
sion using the region name as a covariate was found to
explain much of the variation seen in the single linear
regression and gives an R2 value of 0.650 (adjusted
R2¼ 0.613). Figure 2(d) shows that the residual error
using multi-linear regression is lower and more nor-
mally distributed than single linear regression.
Figure 2(c) shows the multi-linear regression by
region which demonstrates the variability in slope and
intercept between regions. These diﬀerences can be
attributed to two main causes: regional diﬀerences in
bolus transit times meaning that the ASL label image is
acquired before the bolus reaches the tissue, and regio-
nal diﬀerences in tracer extraction. Acquiring ASL data
with multiple post-labelling delay times can be used to
reduce some of this variability and would be particu-
larly helpful when transit time changes are caused by
pathology which cannot be modelled. However, this
multi-linear regression using region as a covariate
provides a good model for the data used here.
To quantify the subject speciﬁc component of the
relationship between normalised ASL-CBF and PET-
R1 which cannot be modelled in a new set of subjects,
multi-linear regression with the subject as a covariate
was performed. This gave an R2 value of 0.436
(adjusted R2¼ 0.358) indicating that there is some
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Figure 2. Correlation of PET-R1 with ASL-CBF for 20 optimisation set subjects where the regression was calculated and applied to
the ASL-CBF data to show the residual error in the fit. (a) PET-R1 against ASL-CBF with single linear regression (black dashed line), (b)
Residual normality plot for single linear regression R1 estimation, inset: histogram of residuals, (c) PET-R1 against ASL-CBF with multi-
linear regression (black dashed lines), (d) Residual normality plot for multi-linear regression R1 estimation, inset: histogram of
residuals.
variation between subjects, but that this accounts for
less of the variation than the variation between regions.
Finally, multi-linear regression using both region and
subject as covariates yielded an R2 value of 0.862
(adjusted R2¼ 0.824), showing that most of the vari-
ation can be explained by these two parameters.
There is insuﬃcient evidence that the data used here
could support a more complex non-linear model, which
supports the linear Renkin–Crone model in equation
(2) under the assumption that PSf  3. Since the multi-
linear regression using region as a covariate is better
able to describe the variation in the data, this model
was selected for use when applying the RT-SRTM in
the subsequent sections.
Extrapolation of PET reference region, CR
Optimisation of PCA CR method. Table 1 shows the per-
centage of the variation described as the number of
components are increased for the population of 39 sub-
jects, C
pop
R½0,60. This demonstrates that six principal com-
ponents are required to describe 99.9% of the variation
within the data; therefore, a maximum of six compo-
nents are used in the optimisation (L 	 6).
Figure 3 shows the MSE in the ﬁt of CR t¼30,60½  using
leave-one-out cross validation and averaged across sub-
jects. This demonstrates that constraining the upper
and lower bounds of the weights reduces the error
when ﬁtting to data with missing timepoints. The
number of components used (L) has less of an inﬂuence
on the error, and overall the combinations of compo-
nents and weight bounds with the lowest error are
L ¼ 6 with either 
 0.5 or 1 times the standard devi-
ation for the bounds, or L¼ 3 with 
 1 times the stand-
ard deviation for the bounds. These three combinations
give a similar MSE for t ¼ 30, 60; however, L ¼ 6 with
1 times the standard deviation for the bounds was
found to perform consistently better across diﬀerent
timing windows, and therefore this was used for com-
parison with the scaled mean CR method in the follow-
ing sections.
Comparison of PCA CR and scaled mean CR methods. The
boxplot in Figure 4(a), which summarises across all
subjects, shows that the PCA CR method performs
better for t ¼ 0, 30 and t ¼ 20, 50; however, the diﬀer-
ence in MSE did not reach statistical signiﬁcance at any
timepoint (p  0:241). The inﬂuence of this error on the
estimation of BPND at diﬀerent acquisition windows is
assessed in the next section.
Optimisation of data acquisition window
The MSE and ME in the estimation of BPND using dif-
ferent data acquisition windows are shown in Table 2.
Extrapolation of CR is not strictly necessary for t¼ 0,30
as it starts from injection; thus, the basis functions can
be generated using the measured data alone. However,
this leads to a higher MSE of 0.1960 due to higher
errors in the computation of the convolution, and
therefore the results given always extrapolate CR for
t¼ 0,30.
In Table 2, the true CR column uses the full mea-
sured CRðt ¼ 0, 60Þ, therefore errors are introduced
purely due to the limited number of datapoints avail-
able. When the later frames are omitted and only
t¼ 0,30min of data are acquired, large errors are intro-
duced as there is little information about the late phase
which contains the signal relating to target binding. As
the time window is shifted later, the MSE and ME are
reduced.
Table 1. The percentage of the variation
explained using increasing number of princi-
pal components following PCA on the
CR t¼0,60½  of 39 optimisation set subjects.
Number of
components (L)
Variation
described (%)
1 76.4
2 95.0
3 97.8
4 99.1
5 99.6
6 99.9
Figure 3. MSE in the fit of CR t¼30,60½  using the PCA CR method
when optimising the number of components used and the upper
and lower bounds for the weights using leave-one-out analysis on
39 optimisation set subjects.
However, the results in Table 2 also show that
there is little to be gained by including data acquired
more than 50min post injection as the error increases.
This is because the signal has plateaued by this point
so, for a ﬁxed 30-minute window, a better ﬁt can be
obtained by including some of the earlier data where
the tracer concentration changes more rapidly over
time. This is further illustrated in Figure 4(b), which
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Figure 4. Box-plots calculated using leave-one-out cross validation in 39 optimisation set subjects. (a) ME in the PCA CR method and
scaled mean CR method compared to measured CR, (b) Error in BPND estimates across different timing windows using different
estimates of CR.
shows the smallest distribution of errors in BPND at
t¼ 20,50.
For the two techniques which extrapolate CR from
the available time window, additional variability is
introduced into the BPND estimates due to errors in
the extrapolation, which is reﬂected by the higher
MSE in Table 2. For both the PCA CR and the
scaled mean CR method, the early phase of the data
becomes more important, as much of the variation
between the CR of subjects is contained in these
frames. This can be seen in Figure 4(a), as for t¼ 0,30
the error in CR estimation is at a minimum and
increases as the acquisition window shifts later. When
the early frames are included, the error in BPND is very
similar to using the true CR, whereas when only the late
frames are used, the error in BPND for the extrapolation
methods increases relative to the true CR, Figure 4(b).
Table 2 shows that the optimal timing window for this
technique is t¼ 20,50min post injection as it yields the
lowest MSE and ME.
The PCA CR method produces a consistently lower
MSE which was statistically signiﬁcantly lower than
that obtained using the scaled mean CR method for
t¼ 20,50 (p¼ 0.002). This is due to the increased ﬂexi-
bility in this method which allows it to better describe
the variation in unseen CR shapes. The PCA CR
method also produces BPND estimates with lower bias
at t¼ 20,50, as demonstrated by the median lines in
Figure 4(b) and the ME in Table 2 (p< 0.001).
Due to the lower MSE and ME, the PCA CR method
with the t¼ 20,50min timing window was selected for
the full implementation of the RT-SRTM in subsequent
sections.
Comparison of proposed RT-SRTM
with gold standard
Figure 5(a) shows BPND, estimated using the
RT-SRTM with t¼ 20,50min of data plotted against
the gold standard BPND. Linear regression of the data
shows that the RT-SRTM method oﬀers a good
approximation of the gold standard as it closely follows
the line of identity (dashed), which is within the 95%
conﬁdence interval (CI) of the regression (shaded). The
linear correlation between the two estimates was tested
using the Pearson correlation coeﬃcient which demon-
strated a high, statistically signiﬁcant result (	¼ 0.896,
p< 0.001, 95% CI [0.875, 0.914]).
To determine the inﬂuence of CBF derived R1 errors
on BPND, sensitivity analysis was performed as
described in the supplementary materials. Brieﬂy,
PET time activity curves were simulated using the real-
istic parameters with a range of noise values30 and ﬁtted
using the optimised RT-SRTM with a ﬁxed R1 error. It
was found that, for regional analysis where noise-
< 3.4%, the mean absolute error was smaller than the
blood ﬂow component found in SUVR in Cselenyi
et al.4 However, if the methodology were to be
extended to voxel-wise analysis, a lower R1 error
would be required due to the increased noise in the
PET data which increases the uncertainty in the
model ﬁt.
Comparison of proposed RT-SRTM with SUVR 1
To ensure a fair comparison between RT-SRTM and
SUVR, SUVR 1 was calculated at ﬁve 10-minute
acquisition windows, starting at t¼ 30, to cover the
recommended time range and compared to the gold
standard BPND, see supplementary materials. The opti-
mal timing window with the lowest bias and error was
found to be t¼ 50,60minutes post injection, which is in
concordance with the literature,4 hence t¼ 50,60 was
used for comparison.
Figure 5(b) shows the amyloid burden estimates gen-
erated for SUVR 1 (t¼ 50,60minutes). Whilst the
correlation between SUVR 1 and BPND is evident,
a positive bias is shown as SUVR 1 overestimates
the binding potential at higher values. This is due to
the fact that the target and reference tissue concentra-
tions reach equilibrium with blood plasma at diﬀerent
points depending on tracer binding, as has been
Table 2. MSE and ME between gold standard BPND and BPND at different 30-min acquisition windows averaged across 16 regions and
39 optimisation set subjects.
Time window (t¼ ts, te) True CR PCA CR Mean CR
0,10 10,20 20,30 30,40 40,50 50,60 MSE ME MSE ME MSE ME
      0.0089 0.0303 0.0085 0.0299 0.0085 0.0299
      0.0035 0.0202 0.0036 0.0202 0.0035 0.0211
      0.0008 0.0050 0.0010 0.0041 0.0012 0.0088
      0.0030 –0.0084 0.0032 –0.0090 0.0034 –0.0050
Note: True CR uses the true reference region curve, PCA CR and mean CR extrapolate the reference region curve using the PCA CRand scaled mean CR
methods, respectively. All methods used the gold standard R1.
explored in detail in the literature.31 The ME quantiﬁes
the bias between the estimates and the gold standard
which is 0.1038 for SUVR 1, indicative of the system-
atic overestimation, compared to 0.0079 for the
RT-SRTM method (p< 0.001). The RT-SRTM
method also has a lower MSE (0.0066 compared to
0.0235 for SUVR 1, p< 0.001), showing that overall
this technique is more accurate at estimating BPND than
the simpliﬁed technique.
This overestimation in SUVR 1 is likely to be a
combination of a linear systematic error in the estima-
tion, as well as the inﬂuence of blood ﬂow. Systematic
error could result from estimating SUVR 1 when not
at steady-state, and could potentially be accounted for
using a population correction factor.
To determine the inﬂuence of blood ﬂow on the esti-
mation of target density, the correlation between esti-
mated target density and tracer delivery was calculated,
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Figure 5. Estimated amyloid burden against the gold standard value calculated using full PET time series for 25 testing set subjects
using 4 different methods: (a) RT-SRTM where t¼ 20,50min (ASL-derived R1), (b) SUVR 1 where t¼ 50,60min, (c) SRTM where
t¼ 0,30min (PET data only, no CR extrapolation), (d) RT-SRTM where t¼ 20,50min (PET data only, extrapolated CR). The grey-shaded
region covers the 95% confidence interval in the regression.
as in Csele´nyi and Farde4 Spearman’s correlation (	)
between R1 and the estimates was calculated, as the
relationship is in theory non-linear. For the gold stand-
ard BPND and BPND using RT-SRTM, there was no
signiﬁcant correlation with R1 (p¼ 0.336 and 0.106
respectively). However, for SUVR 1, there was a sig-
niﬁcant negative correlation (	¼0.226, p< 0.001),
which suggests that the proposed RT-SRTM method
may be more robust to changes in blood ﬂow than
SUVR 1.
Comparison of the proposed RT-SRTM
with short acquisition time PET
Pharmacokinetic modelling can be applied to reduced
acquisition time PET data without incorporating ASL
data in several ways, e.g.: (i) ﬁtting the ﬁrst 30min of
PET data only using the standard SRTM in equation
(1), (ii) extrapolating CR as in RT-SRTM, but R1 is
estimated from the PET data.
For the ﬁrst method, (i), Figure 5(c) compares the
estimation of BPND using the PET data for t¼ 0,30min
to the gold standard. It is evident that the absence of
late-phase data leads to a high error in the estimate,
which is signiﬁcantly higher than using the RT-SRTM
(MSE¼ 0.0813, p< 0.001; ME¼ 0.0569, p< 0.001).
Using the second method, the estimation of BPND
using t¼ 20,50min of PET data and extrapolating
using the PCA CR method, Figure 5(d) shows a signiﬁ-
cantly lower MSE compared to using the ﬁrst 30min
(MSE¼ 0.0121, p< 0.001). The timing window
t¼ 20,50 was selected by calculating the MSE for all
the timing windows used in Table 2 and t¼ 20,50
yielded the lowest value. This method also outperforms
SUVR 1 with a lower MSE (p< 0.001) and ME
(p< 0.001); however, it is signiﬁcantly correlated with
the gold standard R1 (p¼ 0.004).
Comparison of the PET only method with the pro-
posed RT-SRTM including ASL derived R1 estimates
shows that the additional CBF information improves
the estimate of BPND, yielding a signiﬁcantly lower
MSE (p¼ 0.028), ME (p< 0.001) and variance (two-
tailed F-test p< 0.001). This can be seen in Figure 5(a)
where the points are more tightly clustered around the
line of identity when using the proposed RT-SRTM
compared to Figure 5(d) using PET data only.
Discussion
In this paper, we have presented an improved frame-
work for quantitative PET analysis with signiﬁcantly
reduced acquisition time, exploiting blood ﬂow infor-
mation from simultaneously acquired ASL MRI data.
We have demonstrated that the relationship between
the blood ﬂow and tracer delivery for [18F]-ﬂorbetapir,
which is described by the Renkin–Crone model, may be
approximated as regionally linear and used to convert
ASL relative CBF values into pseudo-R1 estimates.
We have also evaluated a new technique for extrapolat-
ing the reference region time activity curve, CR, using
PCA which introduces a lower error than the method
used by Scott et al.,9 where the mean population is
scaled. The timing of the PET acquisition was then
optimised, and found to be t¼ 20,50min post injection.
When the RT-SRTM estimates of BPND using
t¼ 20,50min of PET data and ASL derived R1 were
compared to the gold standard using the full 60min of
PET data, a strong linear correlation was found. This
demonstrates that the RT-SRTM with a 30-min acqui-
sition could potentially be used as a proxy for the full
60-min acquisition for this tracer and subject group.
By comparison, the simpliﬁed measure, SUVR 1,
using 10min of data showed a strong positive bias in
the target density estimation, and the results were cor-
related with the delivery of the tracer as determined by
the gold standard R1 estimates. This implies that, in
addition to systematic error within the SUVR 1 esti-
mates, there is also a bias introduced due to local dif-
ferences in blood ﬂow. This may confound longitudinal
studies, as blood ﬂow may change over time, over the
progression of disease, or due to disease modifying
interventions. Conversely, the RT-SRTM estimates of
target density were not correlated with R1, suggesting
that this technique may be robust to changes in blood
ﬂow and could be a suitable alternative for longitudinal
studies. However, this needs to be validated in a longi-
tudinal dataset.
SUVR 1 estimation at diﬀerent timing windows
showed that t¼ 50,60min gave the best estimation of
BPND. Since SUVR 1 appears to have plateaued by
this point, it is unlikely that the estimation can be
improved by acquiring data at a later timepoint.
This paper focused on the optimisation of a 30-min
PET/MR acquisition. Simultaneous acquisition ensures
that the CBF measured by ASL represents the ﬂow at
tracer injection, avoiding errors introduced by physio-
logical ﬂow changes throughout the day.2 This assumes
negligible change in blood ﬂow between the tracer injec-
tion and the end of the scan. This can be controlled
through measures used for routine clinical PET scans,
such as keeping the patient lying down in an uptake
room from injection to scan start. The inﬂuence of
auditory stimulation, which would be present during
the ASL scan but not during tracer injection, on CBF
should also be considered, and if necessary the condi-
tions in the scanner should be emulated in the uptake
bay. If conditions could be adequately controlled, the
technique could be extended to separate PET and MRI
acquisitions. However, this would be heavily dependent
on the scheduling of the scans and the acquisition time
saved is reduced compared to the simultaneous PET/
MRI method.
A 30-min acquisition was selected to accommodate a
typical MRI neuroimaging session, while still greatly
increasing patient throughput and comfort. This
could be further reduced depending on the MRI data
acquired, where the minimum time is determined by the
acquisition of the ASL data and the images required for
attenuation correction of the PET data. In this case,
using the PCA CR method with fewer principal compo-
nents should be considered to avoid an under-deter-
mined problem where there are more parameters to ﬁt
than datapoints available.
The ASL data used in this study were acquired for
just 5.5min over 50min into the scan with no motion
correction and no patient restraint. For this reason,
approximately 30% of the ASL-CBF maps failed qual-
ity control checks, largely due to motion-induced arte-
facts. This represents a challenging dataset which could
be signiﬁcantly improved by increasing the number of
acquisitions and motion correction. However, the fact
that the RT-SRTM worked so well on this dataset indi-
cates that it could be a clinically useful tool. It is worth
noting that the data acquired from the four clinically
diagnosed YOAD subjects all passed the quality con-
trol checks.
The limited time available within the protocol for the
ASL acquisition also meant that a single delay time
between blood tagging and image acquisition was
used. This yields errors in CBF estimation due to dif-
ferent bolus transit times for diﬀerent brain regions,
either due to normal physiology or pathological
changes. A multi-delay time ASL acquisition would
make the methodology more robust as the transit
time is parameterised within the model and this will
be evaluated in future work.
The RT-SRTM was here applied to an amyloid-b
tracer; however, the methodology could potentially be
used for any tracer which can be described by the
SRTM, and which has a suﬃciently high extraction
fraction, such as [18F]-ﬂutametamol, another amyloid-
b tracer, or tau () tracers.32 The kinetics of these tra-
cers are slower than those of [18F]-ﬂorbetapir, and as
such require longer dynamic acquisitions. Here, the
RT-SRTM could potentially oﬀer a greater reduction
in acquisition time, and in future work, we intend a
comparison with the dual time-window protocol,
another acquisition time reduction method used on
such tracers, where early and late PET data are
acquired with a break in-between.33 Furthermore, our
approach could be broadened to other kinetic models
which have a tracer delivery parameter that can be
approximated using CBF from ASL. Reference region
curve extrapolation could also be used in reference
Logan analysis,34 as an alternative to a previously pro-
posed reduced acquisition time method which cannot
account for blood ﬂow changes.35
The main limitation of this study is that the opti-
misation of the RT-SRTM has been performed on
cross-sectional dynamic scans of mostly healthy volun-
teers. The introduction of subjects with disease may
increase the variability in CR between subjects.
However, some variability already exists in the dataset
used as the healthy subjects undergo normal ageing and
we include four clinically diagnosed subjects, which the
PCA CR method can handle. Provided that the dataset
used to build the model for the PCA CR method
includes diseased subjects, this variability can also be
accounted for.
In future work, this technique will be validated on
longitudinal data including symptomatic patients, to
further investigate its robustness to disease progression
and local changes in blood ﬂow. The linear relationship
found between R1 and relative CBF will require veriﬁ-
cation on such datasets to ensure that the assumption
of PSF  3 still holds in symptomatic subjects.
Another limitation within the proposed technique is
that tracer delivery is estimated directly from ASL-CBF
using a region-dependent linear relationship. This
works well for regional data as artefacts can be aver-
aged out; however, this is not possible for voxel-wise
analysis where errors will propagate through to the R1
estimate. A more robust methodology which propa-
gates database R1 values into the subject space based
on local image similarity has been proposed36 and will
be investigated in the future. This would facilitate
voxel-wise analysis for quantitative parametric imaging
within a clinically feasible time frame.
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